東陽光藥(01558.HK):琥珀酸美託洛爾緩釋片獲批准上市
格隆匯1月10日丨東陽光藥(01558.HK)發佈公吿,公司從廣東東陽光藥業有限公司收購的產品琥珀酸美託洛爾緩釋片(規格:47.5mg及95mg)已獲中國國家藥品監督管理局審批完畢並獲准上市。該產品的上市許可持有人為公司的全資子公司東莞市陽之康醫藥有限責任公司。
根據披露,琥珀酸美託洛爾緩釋片在臨牀上經常用於治療高血壓以及慢性心力衰竭。心肌梗死後以及慢性心力衰竭的患者長期使用琥珀酸美託洛爾緩釋片,可以降低患者的心絞痛發作次數,提高心肌耐受性。該產品屬選擇性β1受體拮抗劑,通過拮抗β1受體,可以抑制交感神經的活性,減慢心率,降低心肌收縮力,從而降低血壓,也降低心肌的耗氧量。
根據艾美仕中國市場數據,琥珀酸美託洛爾緩釋片2020年度市場的銷售額約為2.8億美元,是心血管疾病治療領域的主要品種之一。琥珀酸美託洛爾緩釋片具有良好的臨牀應用價值和市場前景,上市後將成為公司在心血管疾病治療領域的產品之一,在進一步豐富集團的產品組合的同時,也為廣大患者提供質價雙優的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.